This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Selinka, H.-C.
Right arrow Articles by Sapp, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Selinka, H.-C.
Right arrow Articles by Sapp, M.

 Previous Article  |  Next Article 

Journal of Virology, December 2003, p. 12961-12967, Vol. 77, No. 24
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.24.12961-12967.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.

Further Evidence that Papillomavirus Capsids Exist in Two Distinct Conformations

Hans-Christoph Selinka,1 Tzenan Giroglou,1 Thorsten Nowak,1 Neil D. Christensen,2 and Martin Sapp1*

Institute for Medical Microbiology and Hygiene, University of Mainz, D-55101 Mainz, Germany,1 Department of Pathology, Hershey Medical Center, Hershey, Philadelphia, Pennsylvania2

Received 27 May 2003/ Accepted 5 September 2003

Cell surface heparan sulfate proteoglycans (HSPGs) serve as primary attachment receptors for human papillomaviruses (HPVs). To demonstrate that a biologically functional HPV-receptor interaction is restricted to a specific subset of HSPGs, we first explored the role of HSPG glucosaminoglycan side chain modifications. We demonstrate that HSPG O sulfation is essential for HPV binding and infection, whereas de-N-sulfated heparin interfered with VLP binding but not with HPV pseudoinfection. This points to differences in VLP-HSPG and pseudovirion-HSPG interactions. Interestingly, internalization kinetics of VLPs and pseudovirions, as measured by fluorescence-activated cell sorting analysis, also differ significantly with approximate half times of 3.5 and 7.5 h, respectively. These data suggest that differences in HSPG binding significantly influence postbinding events. We also present evidence that pseudovirions undergo a conformational change after cell attachment. A monoclonal antibody (H33.J3), which displays negligible effectiveness in preattachment neutralization assays, efficiently neutralizes cell-bound virions. However, no difference in H33.J3 binding to pseudovirions and VLPs was observed in enzyme-linked immunosorbent assay and virus capture assays. In contrast to antibody H33.B6, which displays equal efficiencies in pre- and postattachment neutralization assays, H33.J3 does not block VLP binding to heparin, demonstrating that it interferes with steps subsequent to virus binding. Our data strongly suggest that H33.J3 recognizes a conformation-dependent epitope in capsid protein L1, which undergoes a structural change after cell attachment.

* Corresponding author. Mailing address: Institut für Medizinische Mikrobiologie und Hygiene, Johannes-Gutenberg-Universität Mainz, Hochhaus am Augustusplatz, D-55101 Mainz, Germany. Phone: 49-6131-393-0211. Fax: 49-6131-393-2359. E-mail: sapp{at}mail.uni-mainz.de.

Journal of Virology, December 2003, p. 12961-12967, Vol. 77, No. 24
0022-538X/03/$08.00+0     DOI: 10.1128/JVI.77.24.12961-12967.2003
Copyright © 2003, American Society for Microbiology. All Rights Reserved.



This article has been cited by other articles:

  • Johnson, K. M., Kines, R. C., Roberts, J. N., Lowy, D. R., Schiller, J. T., Day, P. M. (2009). Role of Heparan Sulfate in Attachment to and Infection of the Murine Female Genital Tract by Human Papillomavirus. J. Virol. 83: 2067-2074 [Abstract] [Full Text]  
  • Day, P. M., Gambhira, R., Roden, R. B. S., Lowy, D. R., Schiller, J. T. (2008). Mechanisms of Human Papillomavirus Type 16 Neutralization by L2 Cross-Neutralizing and L1 Type-Specific Antibodies. J. Virol. 82: 4638-4646 [Abstract] [Full Text]  
  • Yu, K. J., Bashirova, A., Madeleine, M. M., Cheng, J., Johnson, L. G., Schwartz, S. M., Carrington, M., Hildesheim, A. (2007). Evaluation of the Association with Cervical Cancer of Polymorphisms in Syndecan-1, a Heparan Sulfate Proteoglycan Involved with Viral Cell Entry. Cancer Epidemiol. Biomarkers Prev. 16: 2504-2508 [Abstract] [Full Text]  
  • Selinka, H.-C., Florin, L., Patel, H. D., Freitag, K., Schmidtke, M., Makarov, V. A., Sapp, M. (2007). Inhibition of Transfer to Secondary Receptors by Heparan Sulfate-Binding Drug or Antibody Induces Noninfectious Uptake of Human Papillomavirus. J. Virol. 81: 10970-10980 [Abstract] [Full Text]  
  • Knappe, M., Bodevin, S., Selinka, H.-C., Spillmann, D., Streeck, R. E., Chen, X. S., Lindahl, U., Sapp, M. (2007). Surface-exposed Amino Acid Residues of HPV16 L1 Protein Mediating Interaction with Cell Surface Heparan Sulfate. J. Biol. Chem. 282: 27913-27922 [Abstract] [Full Text]  
  • Day, P. M., Thompson, C. D., Buck, C. B., Pang, Y.-Y. S., Lowy, D. R., Schiller, J. T. (2007). Neutralization of Human Papillomavirus with Monoclonal Antibodies Reveals Different Mechanisms of Inhibition. J. Virol. 81: 8784-8792 [Abstract] [Full Text]  
  • Laniosz, V., Nguyen, K. C., Meneses, P. I. (2007). Bovine Papillomavirus Type 1 Infection Is Mediated by SNARE Syntaxin 18. J. Virol. 81: 7435-7448 [Abstract] [Full Text]  
  • Artemenko, A. G., Muratov, E. N., Kuz'min, V. E., Kovdienko, N. A., Hromov, A. I., Makarov, V. A., Riabova, O. B., Wutzler, P., Schmidtke, M. (2007). Identification of individual structural fragments of N,N'-(bis-5-nitropyrimidyl)dispirotripiperazine derivatives for cytotoxicity and antiherpetic activity allows the prediction of new highly active compounds. J Antimicrob Chemother 60: 68-77 [Abstract] [Full Text]  
  • Buck, C. B., Day, P. M., Thompson, C. D., Lubkowski, J., Lu, W., Lowy, D. R., Schiller, J. T. (2006). Human {alpha}-defensins block papillomavirus infection. Proc. Natl. Acad. Sci. USA 103: 1516-1521 [Abstract] [Full Text]  
  • Richards, R. M., Lowy, D. R., Schiller, J. T., Day, P. M. (2006). Cleavage of the papillomavirus minor capsid protein, L2, at a furin consensus site is necessary for infection. Proc. Natl. Acad. Sci. USA 103: 1522-1527 [Abstract] [Full Text]  
  • Kamper, N., Day, P. M., Nowak, T., Selinka, H.-C., Florin, L., Bolscher, J., Hilbig, L., Schiller, J. T., Sapp, M. (2006). A Membrane-Destabilizing Peptide in Capsid Protein L2 Is Required for Egress of Papillomavirus Genomes from Endosomes. J. Virol. 80: 759-768 [Abstract] [Full Text]  
  • Pyeon, D., Lambert, P. F., Ahlquist, P. (2005). Production of infectious human papillomavirus independently of viral replication and epithelial cell differentiation. Proc. Natl. Acad. Sci. USA 102: 9311-9316 [Abstract] [Full Text]  
  • Cavaldesi, M., Caruso, M., Sthandier, O., Amati, P., Garcia, M. I. (2004). Conformational Changes of Murine Polyomavirus Capsid Proteins Induced by Sialic Acid Binding. J. Biol. Chem. 279: 41573-41579 [Abstract] [Full Text]  
  • Day, P. M., Baker, C. C., Lowy, D. R., Schiller, J. T. (2004). Establishment of papillomavirus infection is enhanced by promyelocytic leukemia protein (PML) expression. Proc. Natl. Acad. Sci. USA 101: 14252-14257 [Abstract] [Full Text]  
  • Florin, L., Becker, K. A., Sapp, C., Lambert, C., Sirma, H., Muller, M., Streeck, R. E., Sapp, M. (2004). Nuclear Translocation of Papillomavirus Minor Capsid Protein L2 Requires Hsc70. J. Virol. 78: 5546-5553 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»